CorMedix (CRMD) Non Operating Investment Income (2015 - 2026)

CorMedix (CRMD) posted Non Operating Investment Income of $2.3 million for Q4 2025, down 26.46% sequentially from $3.1 million in Q3 2025.

CorMedix (CRMD) Non Operating Investment Income (2015 - 2026) Analysis & Trends

CorMedix has reported Non Operating Investment Income for 6 years, with the latest figure at $2.3 million in Q4 2025.

Quarterly Non Operating Investment Income changed N/A year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.4 million (changed N/A YoY) and the FY2025 annual result came in at $5.4 million, changed N/A from the prior year.
Non Operating Investment Income fell to $2.3 million in Q4 2025 per CRMD's latest filing, from $3.1 million in the prior quarter.
Over five years, Non Operating Investment Income peaked at $3.1 million in Q3 2025 and troughed at $2.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn	2.55 Mn

Download Data